Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Learn what you need to know about cash back taxes to optimize your financial strategies. Stay ahead in tax planning.
25,545 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Workday posted a solid Q4 beat on earnings and revenue, yet forward guidance disappointed investors. Shares tumbled a...
Goldman Sachs raises price targets on three major tech names by roughly 10%, reflecting improved growth visibility as...
Northcoast downgraded Norwegian Cruise Line amid macro headwinds, signaling tougher times for the sector as Middle Ea...
Virtus InfraCap U.S. Preferred Stock ETF (PFFA) shows a 9.6% distribution yield, driven by borrowed funds. This artic...
Major U.S. banks are moving to launch a tokenized deposit network in 2027, aiming to bridge traditional payments with...
Johnson & Johnson shares jump as the company pushes through a resilient oncology lineup and strategic investments, li...
Strategy reported a dramatic second quarter loss tied to its Bitcoin holdings, even as the company bought more BTC ov...
Markets keep climbing amid strong earnings and AI-led investment. This article explains why this bull market crushing...
C3.ai reports after the bell, with traders watching for signals on revenue, margins and AI platform uptake. This live...
Permanent Portfolio's Michael Cuggino argues Meta can invest heavily in AI without sacrificing profits. He emphasizes...
Core Scientific reports higher first-quarter revenue and gross profit, yet a net loss due to impairment charges derai...